Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Rituximab 8Vincristine 5Doxorubicin 5Cyclophosphamide 5Methotrexate 4Cytarabine 4Bortezomib 4Radiotherapy 3Prednisone 3Bendamustine Hydrochloride 3Peripheral Blood Stem Cell Transplantation 2Melphalan 2Leucovorin 2Dexamethasone 2CT-P10 2zanubrutinib 1obinutuzumab 1merphos 1liposomal amphotericin B 1ixabepilone 1ibritumomab tiuxetan 1fludarabine phosphate 1carmustine, poliferprosan 20 drug combination 1alvocidib 1acalabrutinib 1Whole-Body Irradiation 1Watchful Waiting 1Vancomycin 1Tazobactam 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, Mantle-Cell × Hyaluronoglucosaminidase × Clear all
NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡